Search

Genmab A-S

Geschlossen

2,121 -1.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2094

Max

2161

Schlüsselkennzahlen

By Trading Economics

Einkommen

243M

295M

Verkäufe

259M

1.2B

KGV

Branchendurchschnitt

26.113

57.366

EPS

34.85

Gewinnspanne

25.541

Angestellte

3,119

EBITDA

216M

431M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

-1.49% downside

Dividenden

By Acuity

Nächstes Ergebnis

5. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

16B

130B

Vorheriger Eröffnungskurs

2122.85

Vorheriger Schlusskurs

2121

Genmab A-S Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Aug. 2026, 23:56 UTC

News

Array Technologies has acquired Affordable Wire Management, enhancing its portfolio and growth potential. Shares are trading slightly higher in after-market hours.

31. Aug. 2026, 23:56 UTC

MannKind Corp shares are lower in after-market trading, continuing a trend observed over the past four sessions amid rising oil prices and inflation concerns.

31. Aug. 2026, 23:56 UTC

Correlated Moves

Regal Rexnord Corp shares are higher in after-market trading, reflecting a cumulative return of 0.44% since Monday's close amid similar trends from Eaton Corporation PLC.

31. Aug. 2026, 23:56 UTC

Schrodinger Inc shares are higher in after-hours trading, influenced by rising oil prices and inflation concerns ahead of the Federal Reserve meeting.

31. Aug. 2026, 23:56 UTC

Mosaic Co's shares are lower in after-market hours, reflecting inflation concerns from rising oil prices ahead of the Federal Reserve meeting.

31. Aug. 2026, 23:56 UTC

TransDigm Group Inc shares are lower in after-market hours. No specific news was identified to explain the decline amid overall weak market performance.

31. Aug. 2026, 23:56 UTC

News

Frontier Group Holdings plans to terminate leases for 13 A320neo aircraft, leading to anticipated charges of $60 million to $80 million. Shares are lower in after-market hours.

31. Aug. 2026, 23:56 UTC

Exelon Corp shares are lower in after-market trading, following fluctuations since Monday's close. Rising oil prices and inflation concerns influence broader market sentiment.

31. Aug. 2026, 23:56 UTC

Shell PLC shares are lower in after-market trading, following a slight decline since Monday's close. Oil prices have risen, impacting broader market sentiment.

31. Aug. 2026, 23:56 UTC

abrdn Physical Palladium Shares ETF traded roughly flat after-market hours, with no specific news identified. Global equity indices are mixed amid inflation concerns.

31. Aug. 2026, 23:52 UTC

Japan's Q2 2026 Capital Spending YoY forecasted to rise only 0.2%, signaling subdued private investment growth amid cautious market sentiment.

31. Aug. 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on September 1 faces cautious market sentiment amid rising oil prices and inflation concerns.

31. Aug. 2026, 23:52 UTC

Federal Reserve Chair Kevin Warsh's hawkish remarks boost interest rate hike expectations to 60-65% amid rising inflation concerns and geopolitical tensions.

31. Aug. 2026, 23:52 UTC

ISM Manufacturing Employment Data Release on September 1, 2026, Sparks Caution Amid Inflation Concerns and Fed Rate Hike Speculation.

31. Aug. 2026, 23:52 UTC

ISM Manufacturing PMI Release on September 1 Expected to Show Continued Growth Amid Geopolitical Tensions and Fed Rate Hike Speculation.

31. Aug. 2026, 23:52 UTC

Australia's Balance of Trade data set for September 3, 2026, anticipates a AUD 1.4 billion surplus amid mixed market sentiment and geopolitical tensions affecting investor confidence.

31. Aug. 2026, 23:52 UTC

JOLTs Job Openings Report on September 1 Expected to Influence Fed Rate Hike Decisions Amid Geopolitical Tensions and Inflation Concerns.

31. Aug. 2026, 23:52 UTC

U.S. Initial Jobless Claims Expected at 205K Amid Inflation Concerns and Fed Rate Hike Speculation

31. Aug. 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Rate Expected at 0.3%, Sparking Speculation of Interest Rate Hike Amid Mixed Economic Sentiment

31. Aug. 2026, 23:52 UTC

Japan's Q2 2026 GDP Growth Release Expected at 1.1% Amid Mixed Economic Signals and Potential BoJ Interest Rate Hikes

31. Aug. 2026, 23:51 UTC

Enterprise Financial Services Corp shares are lower in after-market trading, lacking any specific news to explain the decline. The stock remains below its 20-day moving average.

31. Aug. 2026, 23:51 UTC

Dyadic International Inc shares are higher in after-market hours, showing strong buying interest despite a recent significant decline and downward pressure over the past sessions.

31. Aug. 2026, 23:51 UTC

Wayfair Inc shares are lower in after-market trading, reversing a trend of higher daily closes. No specific news was identified to explain the decline.

31. Aug. 2026, 23:51 UTC

United Parks & Resorts Inc. shares are higher in after-market trading, reflecting notable strength despite no specific company news identified.

31. Aug. 2026, 23:51 UTC

Playtika Holding Corp shares are higher in after-market trading. No specific news was identified to explain this movement amid broader market volatility.

31. Aug. 2026, 23:51 UTC

European equity markets decline amid rising oil prices and inflation concerns following U.S.-Iran military tensions, with investors cautious ahead of key economic data.

31. Aug. 2026, 23:51 UTC

U.S. equity indices decline amid rising oil prices and geopolitical tensions, with Fed rate hike expectations intensifying.

31. Aug. 2026, 23:51 UTC

Asia equity markets mixed as Middle East tensions and hawkish Fed signals drive oil prices up and investor caution.

31. Aug. 2026, 23:51 UTC

U.S. and European markets decline amid rising oil prices and inflation fears following U.S.-Iran tensions, while Dallas Fed Manufacturing Index signals strong recovery.

31. Aug. 2026, 23:51 UTC

Helmerich and Payne Inc. shares are higher in after-market trading, supported by a rise in Brent crude futures amid geopolitical tensions in the Strait of Hormuz.

Peer-Vergleich

Kursveränderung

Genmab A-S Prognose

Kursziel

By TipRanks

-1.49% Nachteil

12-Monats-Prognose

Durchschnitt 2,493.35 DKK  -1.49%

Hoch 3,320 DKK

Tief 308.417 DKK

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Genmab A-S – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

7 ratings

3

Buy

2

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat